Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
OwnerMark A. Exley, Samuel B. Wilson +1inventors
InventorsMark A. Exley, Samuel B. Wilson, Steven P. Balk
Life of this patent
Estimating the term…
Abstract
The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and JαQ+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.
Claims42
A purified antibody that preferentially binds a T cell antigen receptor (TCR), wherein said antibody preferentially binds a CDR3-loop or an α-β junction of said TCR;
- or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.
A combination of purified antibodies that preferentially binds a TCR, wherein said antibody combination preferentially binds a CDR3-loop or an α-β junction of said TCR;
- or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
- wherein said antibody combination is selected from the group consisting of:
- (i) an anti-Vα24 antibody and an anti-CD161 antibody;
- (ii) an anti-Vα24 antibody and an anti-CD94 antibody;
- (iii) an anti-Vβ11 antibody and an anti-CD161 antibody;
- and
- (iv) an anti-Vβ11 antibody and an anti-CD94 antibody.
A fragment or derivative of an antibody, wherein said antibody preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.
A bifunctional antibody comprising:
- (a) a first antibody or fragment thereof that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
- wherein said first antibody or fragment binds a first epitope;
- and
- (b) a second antibody or fragment thereof that binds a second epitope expressed on a T cell expressing said TCR or expressed on a NK T cell, CD1d-reactive T cell, or JαQ+ T cell that is bound by said first antibody or fragment thereof.
A stable hybridoma that produces an antibody, wherein said antibody preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.
A purified T cell subpopulation, wherein said T cells are specifically bound by an antibody or a combination of antibodies, wherein said antibody or said antibody combination preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or wherein said antibody preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.
A method of generating an antibody that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
- said method comprising:
- (a) coupling a cyclic peptide to a carrier;
- (b) immunizing a mammal with said coupled peptide;
- and
- (c) isolating an antibody that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.
A method of generating an antibody that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
- said method comprising:
- (a) immunizing a CD1 or invariant T cell deficient mammal with invariant T cells;
- and
- (b) isolating an antibody that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.
A method of measuring the amount of NK TCRs or the amount of NK T cells in a sample, said method comprising contacting said sample with an antibody that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.
A method of measuring the amount of CD1d-reactive TCRs or the amount of CD1d-reactive T cells in a sample, said method comprising contacting said sample with an antibody that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.
A method of measuring the amount of JαQ+ TCRs or the amount of JαQ+ T cells in a sample, said method comprising contacting said sample with an antibody or a combination of antibodies that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.
A method of visualizing the NK TCRs or the NK T cells in a sample, said method comprising contacting said sample with an antibody that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.
A method of visualizing the CD1d-reactive TCRs or the CD1d-reactive T cells in a sample, said method comprising contacting said sample with an antibody that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.
A method of visualizing the JαQ+ TCRs or the JαQ+ T cells in a sample, said method comprising contacting said sample with an antibody or a combination of antibodies that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.
A method of diagnosing a subject with a condition or an increased risk for a condition selected from the group consisting of autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer;
- said method comprising the following:
- (a) contacting a sample from said subject with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
- (b) quantitating the amount of said antibody or said antibody combination bound to said TCR or said T cells;
- thereby determining the amount of T cells of interest in said sample;
- and
- (c) comparing the amount of said T cells of interest in said sample to the amount of said T cells of interest found in subjects diagnosed with said condition or subjects not diagnosed with said condition.
A method of treating or preventing an autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, or cancer in a mammal, said method comprising administering to said mammal an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.
A method of inhibiting T cell pathogenesis in a mammal, said method comprising administering to said mammal an antibody or a combination of antibodies that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs;
- or inhibits the expansion of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
- said administering sufficient to inhibit a T cell expressing said TCR, a NIK T cell, a CD1d-reactive T cell, or a JαQ+ T cell.
A method of increasing the size of a subpopulation of T cells, said method comprising contacting a sample comprising said T cells with an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, JαQ+ T cells, and T cells expressing a CDR3-loop or an α-β junction of a TCR that is preferentially bound by said antibody, wherein said contacting occurs under conditions that result in an increase in the number of said T cells.
A method of increasing the size of a subpopulation of T cells, said method comprising:
- (a) contacting a sample comprising said T cells with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
- said contacting conducted under conditions that allow complex formation between said T cells and said antibody or said combination of antibodies;
- (b) isolating said complex;
- and
- (c) contacting said T cells in said complex or recovered from said complex with an antigen and antigen presenting cells under conditions that allow said contacting to increase the number of said T cells;
- wherein said antigen is not α-galactosylceramide.
A method of increasing the size of a subpopulation of T cells, said method comprising:
- (a) contacting a sample comprising said T cells with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
- said contacting conducted under conditions that allow complex formation between said T cells and said antibody or said combination of antibodies;
- (b) isolating said complex;
- and
- (c) contacting said T cells in said complex or recovered from said complex with an antigen and antigen presenting cells under conditions that allow said contacting to increase the number of said T cells;
- wherein said antigen is wherein said antigen is α-galactosylceramide.
A method of increasing the size of a subpopulation of T cells in a mammal, said method comprising:
- (a) obtaining a sample comprising said T cells from said mammal;
- (b) contacting said T cells with an antibody or a combination of antibodies that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, JαQ+ T cells, and T cells expressing a CDR3-loop or an α-β junction of a TCR that is preferentially bound by said antibody or said antibody combination;
- said contacting conducted under conditions that allow said contacting to increase the number of said T cells;
- and
- (c) administering said contacted T cells to said mammal.
A method of increasing the size of a subpopulation of T cells in a mammal, said method comprising:
- (a) obtaining a sample comprising said T cells from said mammal;
- (b) contacting said T cells with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
- said contacting conducted under conditions that allow complex formation between said T cells and said antibody or said combination of antibodies;
- (c) isolating said complex;
- and
- (d) contacting said T cells in said complex or recovered from said complex with an antigen and antigen presenting cells under conditions that allow said contacting to increase the number of said T cells;
- wherein said antigen is not α-galactosylceramide;
- and
- (e) administering said contacted T cells to said mammal.
A method of increasing the size of a subpopulation of T cells in a mammal, said method comprising:
- (a) obtaining a sample comprising said T cells from said mammal;
- (b) contacting said T cells with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
- said contacting conducted under conditions that allow complex formation between said T cells and said antibody or said combination of antibodies;
- (c) isolating said complex;
- and
- (d) contacting said T cells in said complex or recovered from said complex with an antigen and antigen presenting cells under conditions that allow said contacting to increase the number of said T cells;
- wherein said antigen is α-galactosylceramide;
- and
- (e) administering said contacted T cells to said mammal.
A method of purifying a subpopulation of T cells from a sample, said method comprising contacting said sample with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR;
- or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.
Dependencies are inferred from the claim text.